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Background: Nectin-4 belongs to the nectin family that has diverse physiological and pathological functions in
humans. Recent studies have also suggested some roles for Nectin-4 in several human cancers. However, the
precise roles and clinical relevance of Nectin-4 in tumors are largely unknown.
Methods: Nectin-4 expression was investigated in 123 patients with pancreatic cancer by immunohistochemistry.
Furthermore, we investigated the association of Nectin-4 in pancreatic cancer with tumor proliferation, angiogenesis
and immunity by using immunohistochemistry and siRNA interference method.
Results: Patients with high Nectin-4 expression had poorer postoperative prognosis than those with low expression.
Importantly, multivariate analysis indicated that Nectin-4 expression had a significant independent prognostic value
in pancreatic cancer (HR = 1.721, 1.085-2.730; P = 0.021). Tumor Nectin-4 expression was significantly correlated with
Ki67 expression. In addition, siRNA-mediated gene silencing of Nectin-4 significantly inhibited the cell proliferation in
human pancreatic cancer cells, Capan-2 and BxPC-3. Furthermore, Nectin-4 expression was also positively correlated
with VEGF expression and intratumoral microvessel density. However, there were no significant correlations of tumor
Nectin-4 expression with tumor-infiltrating T cells.
Conclusion: Nectin-4 is a significant prognostic predictor, and may play a critical role in pancreatic cancer. Nectin-4
may be novel therapeutic target for pancreatic cancer.
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Pancreatic cancer is highly aggressive and is the fourth
leading cause of cancer deaths in the Unite States, and the
number of patients has been increasing [1]. Although
several advancements in the treatment including new
reagents and regimens of chemotherapy and radiotherapy
have recently been introduced, the prognosis of patients
remains poor [2-7]. Although curative surgical resection
has been considered to be the only chance for cure or
long-term survival, more than half of the patients already
have distant metastases at the time of initial evaluation
[8]. Therefore, the surgery is indicated for only 20-30% of* Correspondence: m-sho@naramed-u.ac.jp
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unless otherwise stated.patients [6]. Thus, the identification of novel targets and
development of new therapeutic approaches are required
to improve patient prognosis [9-11].
The nectins (Nectin-1, Nectin-2, Nectin-3, and
Nectin-4) and nectin-like molecules (Necl) are families
of Ca2 + -independent immunoglobulin-like cell adhesion
molecules. These members are important in the formation
and maintenance of adherens junctions and tight junctions
[12-14]. Furthermore, each member has also diverse
functions and acts independently or interactively. Although
Nectin-1, 2, and 3 are widely expressed in normal adult tis-
sues, Nectin-4, also known as PVRL4 (poliovirus-receptor-
like 4), is expressed specifically in the embryo and placenta
[15,16]. It was recently reported that Nectin-4 is overex-
pressed in several human cancers, including lung, ovarian,
and breast cancer [17-20]. It was also demonstrated that atral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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marker for several cancers [17-20]. Furthermore, a few
clinical studies have shown that there were significant
inverse correlations between tumor Nectin-4 expression
and the prognosis of the patients with lung and breast
cancers [17,19].
Besides these clinical studies, several recent basic studies
have revealed that the potential roles and functions of
Nectin-4 in tumor biology [15,16,19,21]. One study has
shown that Nectin-4 contributes to the cell growth and
proliferation of tumors through the Rac1-signaling path-
way in human lung adenocarcinoma cells [19]. In other
study, Nectin-4 promotes the attachment of individual
cells to each other on a juxtaposed cell, and maintains the
transformed properties of breast cancer cells in vitro. In
addition, the knockdown of Nectin-4 by transfection of
siRNA or the intravenous injections of anti-Nectin-4
monoclonal antibody inhibits tumor growth and reduces
cell-cell contact in breast cancer cell lines in vivo [21].
Furthermore, Nectin-4 may have unknown functions, since
other nectins and Necls are reported to play important
roles in various conditions including acquired immunity
and angiogenesis [22-27].
Although the accumulating evidence indicates that
Nectin-4 may play a critical role in tumor biology, the
precise roles of Nectin-4 in tumor progression and
metastasis in human cancers are not fully elucidated.
Furthermore, to our knowledge, its clinical significance in
pancreatic cancer has not been addressed. In this study,
we tried to clarify the clinical importance of Nectin-4
expression in human pancreatic cancer. In addition,
based on the previous studies on Nectin-4, we aimed to




We examined 123 pancreatic cancer patients who had
undergone surgery at Nara Medical University Hospital
between 1992 and 2008. The median age of the patients
was 66 years, with a range of 33 to 82 years. No one re-
ceived preoperative anticancer treatment. All tumors were
diagnosed as pancreatic ductal adenocarcinoma. Tissues,
both cancerous and non-cancerous, were obtained from
resected specimens and were then rapidly frozen at -80°C
for storage until use. The remainder of each specimen was
fixed in 10% phosphate-buffered formalin and embedded
in paraffin. Tumors were classified according to the TNM
staging system of the International Union Against Cancer
(UICC) [28]. Follow-up was until death or January 2014.
Written informed consent was obtained from all patients
before treatment, according to our institutional guidelines.
This study was approved by the institutional review board
(Nara Medical University Ethics Committee).Cell lines and culture
The human pancreatic cancer cell lines, Capan-2 and
BxPC-3 were obtained from RIKEN BioResource Center
and cultured in RPMI 1640 supplemented with 10%
heat-inactivated fetal bovine serum (FBS).
Immunohistochemistry
The paraffin embedded full sections were stained using a
DAKO EnVision system (DAKO Cytomation, Japan),
according to the manual provided by the manufacturer.
As primary antibodies, the anti-human Nectin-4 anti-
body (AF2659, 1:40 dilution; R&D Systems, USA) was
used. The anti-human CD4, CD8, CD45RO, CD31, and
Ki67 antibodies (DAKO) were also used. Formalin-fixed,
paraffin-embedded tissues were cut into 5-μm sections,
deparaffinized, and rehydrated in a graded series of etha-
nol. Antigen retrieval was done by heating tissue sections
using a Target Retrieval Solution, pH 9.0 (DAKO). To
block endogenous peroxidase, sections were immersed in
0.3% solution of hydrogen peroxide in absolute methanol
for 5 minutes at room temperature and washed in fresh
PBS for 3 times, each of 5 minutes duration. Purified each
mAb was added and incubated overnight at 4°C. Sections
were washed in PBS for 3 times, each of 5 minutes
duration, and then we use EnVision+, Mouse/HRP or
Rabbit/HRP (DAKO) according to the instructions of
the manufacturer. Sections were counterstained with
hematoxylin, dehydrated in ethanol, cleared in xylene,
and coverslipped.
Evaluation of immunostaining
Immunohistochemistry for Nectin-4, at least 200 tumor
cells were scored per field at × 400 magnification. The
positive cell was defined as the cells with strongly and
clearly brown immunostained cytoplasm. Specimens
with a ≥50% Nectin-4 positive tumor cells were classified
as Nectin-4 high status, and others were as Nectin-4
low. Since staining was constantly intense in most cases,
the intensity of each sample was not counted in this study.
Immunohistochemistry for CD4+, CD8+, and CD45RO+
T cells was evaluated. An average number of >50 accumu-
lating CD4+, CD8+, and CD45RO+ tumor-infiltrating T
lymphocytes (TILs) per field at × 200 magnification were
scored in five fields. For the microvessel counting, the five
most highly vascularized areas were counted at × 200
magnification, and the average counts were recorded
[29,30]. The mean microvessel count of these tumors was
55.9. To evaluate the Ki67 expression, at least 1,000 tumor
cells were scored in the invasive front of tumors at a mag-
nification of × 400, and the percentage of tumor cells
showing positive staining was calculated [31]. We classi-
fied into two groups according to the median of positivity
of Ki67 expression. Authorized two pathologists who had
no knowledge of the patients’ clinical status and outcome
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the slides were re-evaluated until agreement was reached.Extraction of total RNAs and real-time reverse
transcriptase polymerase chain reaction (PCR) analysis
Total RNA was isolated from resected frozen specimens
by using RNAspin Mini (GE Healthcare, Tokyo, Japan)
and the first-strand cDNA was synthesized from 1 μg RNA
using a high-capacity cDNA reverse transcription kit
(Applied Biosystems, USA), according to the manufacturer’s
protocol. Real-time quantitative PCR analysis was carried
out using an ABI Prism 7700 sequence detector system
(Applied Biosystems). All primer/probe sets were purchased
from Applied Biosystems. PCR was carried out using the
TaqMan Universal PCR Master Mix (Applied Biosystems)
using 1 μl of cDNA in a 20 μl final reaction volume. The
PCR thermal cycle conditions were as follows: initial
step at 95°C for 10 min, followed by 40 cycles of 95°C for
15 seconds and 60°C for 1 min. The expression level of
the housekeeping gene β2-microglobulin was measured as
an internal reference with a standard curve to determine
the integrity of template RNA for all specimens. The ratio
of the mRNA level of each gene was calculated as follows:
(absolute copy number of each gene)/(absolute copy
number of β2-microglobulin).Small interfering RNA (siRNA) transfection of Nectin-4
For our transfection analyses, Capan-2 and BxPC-3 cells
were seeded in 6-well plates, and transfected either with
control RNA (Santa Cruz Biotechnology, USA) or with
10 nM of siRNA of Nectin-4. Transfections were carried
out using the Lipofectamine system (Invitrogen) in ac-
cordance with the manufacturer’s protocol when cells
ware achieved about 30% confluent. The Nectin-4
siRNA duplexes, generated with 30-dTdT overhangs and
prepared by QIAGEN (USA), were chosen against the DNA
target sequences as follows: (Nectin-4 target sequence:
5′-CAGAGCAGTATTAATGATGCA-3′).Cell viability assay
Cell viability was determined using the Cell-titer 96 aque-
ous one solution cell proliferation assay kit, according to
the instruction manual (Promega Corporation, USA).
Briefly, aliquots of 1 × 103 cells per well were cultured in
96-well plates with Nectin-4 or control siRNA for 72 hours.
After incubation, MTS [3-(4,5-dimethyl-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt] reagent (Promega) was added to each well and
incubated for an additional 1 hour. The absorbance at
492 nm was recorded with a 96-well plate reader. Each
experiment was performed in triplicate and repeated at
least thrice.Preparation of cell lysates and Western blot analysis
We resolved the cell lysates in SDS-polyacrylamide gels
and transferred them onto polyvinylidene difluoride mem-
branes (Millipore, Ltd. USA), which were then blocked in
5% skim milk at room temperature for 1 hour. The mem-
branes were incubated with the indicated the anti-human
PVRL4 antibody (ab192033, 1:1000 dilution; Abcam, UK)
overnight at 4°C, and then incubated with horseradish
peroxidase-conjugated IgG (Santa Cruz Biotechnology).
We detected peroxidase activity on X-ray films using an
enhanced chemiluminescence detection system.
Statistical analysis
The overall survival time was calculated from the date of
surgery to the date of death. Kaplan–Meier survival
calculations and the corresponding log-rank tests were
carried out to determine differences in survival rates.
Multivariate analysis was done using the Cox regression
model. We used the term of residual tumor status as R
factor, tumor status as T factor, nodal status as N factor,
and metastatic status as M factor in tumor-node-
metastasis classification, respectively. The chi-square test
or Fisher’s exact test was used to analyze the significance
of the association between the expression of Nectin-4 and
clinicopathological factors. Other data were analyzed
using the Student’s t test or the Mann-Whitney U
test as appropriate to determine significant differences.
The Spearman’s rank test was also used to determine the
correlation between two variables. A P value <0.05 was
considered statistically significant. The statistical analyses
were performed using the SPSS® software program, version
19.0 (SPSS, Chicago, IL, USA).
Results
Nectin-4 expression and prognostic value in human
pancreatic cancer
We first evaluated the Nectin-4 expression in 123 actual
human pancreatic cancer tissues by immunohistochemistry.
Nectin-4 was abundant and expressed mainly in the plasma
membrane and cytoplasm of cancer cells (Figure 1A). On
the other hand, there was limited expression of Nectin-4 in
non-cancer tissues including islet cells, acinar cells and
normal gland (Figure 1C). Overall, the mean percentage of
Nectin-4 positive cells in pancreatic cancer tissues was
51.4% (standard deviation 23.5%). Each sample was classi-
fied into two groups according to more or less than 50% of
positivity of Nectin-4 expression (Figure 1A,B). As a result,
69 (56.1%) patients were classified as high, while 54
(43.9%) patients were classified as low. Interestingly,
the patients with Nectin-4 high tumor had significantly
poorer postoperative prognosis than patients with Nectin-4
low (P = 0.013, Log-rank test; Figure 2). The median sur-
vival times were 426 days in the patients with Nectin-4 high
and 682 days in Nectin-4 low. Postoperative recurrence
Figure 1 Nectin-4 expression in human pancreatic cancer
tissues. (A,B) Tumor cell with high or low Nectin-4 expression.
(C) There was limited expression of Nectin-4 in non-cancer tissues
including islet cells, acinar cells and normal gland. Representative
case of tumor Nectin-4 expression. Original magnification, ×200.
Figure 2 Prognostic value of Nectin-4 status in human pancre-
atic cancer. Overall survival of 123 patients with pancreatic cancer
according to tumor Nectin-4 status. Patients with tumors of high
Nectin-4 expression had significantly poorer prognosis than those
with the low expression (P = 0.013).
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low group at the time of analysis. The recurrence pattern in
Nectin-4 high group was hematogenous in 31 (44.9%), local
in 33 (47.8%), and peritoneal in 19 (27.5%). In Nectin-4
low group, those were 16 (29.6%), 25 (46.3%), and 17
(31.5%), respectively. There was no significant difference
in recurrence pattern between two groups.
Next, we evaluated the correlations of the Nectin-4
expression with various clinicopathological factors. Therewere no significant differences between two groups in any
clinicopathological findings including TNM status and
pathological UICC stage (Table 1).
Correlation between the Nectin-4 and Ki67 expression in
human pancreatic cancer
Next, to further investigate the functions of Nectin-4 in
pancreatic cancer, we evaluated the involvement of
Nectin-4 in pancreatic cancer cell proliferation. We ana-
lyzed the correlation of Nectin-4 with Ki67, a proliferation
marker, by immunohistochemistry (Figure 3A). Overall, the
mean percentage of Ki67-positive tumor cells was 19.8%.
The percent of Nectin-4 expression level was significantly
correlated with the Ki67 expression level (R = 0.436,
P < 0.001; Figure 3B). Furthermore, the Ki67-positive rate
was significantly higher in the tumors with Nectin-4 high
status than in tumors with Nectin-4 low (25.4 ± 1.7 vs.
12.7 ± 1.1%, P < 0.001; Figure 3C). These data suggested
that Nectin-4 might contribute to tumor proliferation in
human pancreatic cancer.
Univariate and multivariate prognostic analysis of
patients with pancreatic cancer
In the univariate analysis of the overall survival, high
Nectin-4 expression was significant prognostic factor
(HR =1.628, P = 0.014). For prognostic analysis, patients
were categorized by the median age. The tumor status and
histopathological grading were categorized according to
the prognostic value determined by preliminary analysis.
As a result, the other factors that significantly correlated
with the patients’ overall survival were the tumor status,
Table 1 Comparison of clinicopathological characteristics
according tumor Nectin-4 expression








male 72 30 (55.6) 42 (60.9) 0.584
female 51 24 (44.4) 27 (39.1)
Age, year
< 66 59 27 (50.0) 32 (46.4) 0.690
>66 64 27 (50.0) 37 (53.6)
Histopathological grading
G1 34 13 (24.1) 21 (30.4) 0.873
G2 71 33 (61.1) 38 (55.1)
G3 14 6 (11.1) 8 (11.6)
G4 4 2 (3.7) 2 (2.9)
Tumor status
T1 8 4 (7.4) 4 (5.8) 0.299
T2 21 13 (24.1) 8 (11.6)
T3 84 33 (61.1) 51 (73.9)
T4 10 4 (7.4) 6 (8.7)
Nodal status
N0 50 24 (44.4) 26 (37.7) 0.466
N1 73 30 (55.6) 43 (62.3)
Metastatic status
M0 112 49 (90.7) 63 (91.3) >0.999b
M1 11 5 (9.3) 6 (8.7)
UICC stage
IA, IB 21 13 (24.1) 8 (11.6) 0.358
IIA 26 10 (18.5) 16 (23.2)
IIB 60 25 (46.3) 35 (507)
III 5 1 (1.8) 4 (5.8)
IV 11 5 (9.3) 6 (8.7)
aChi-square test, bFisher’s exact test.
UICC International Union Against Cancer.
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Ki67 status. Furthermore, multivariate analysis indicated
that tumor Nectin-4 status was a significant independent
prognostic factor (HR = 1.721, P = 0.021) (Table 2). In
addition, metastatic status and residual tumor status were
defined as independent prognostic factors (Table 2). Taken
together, these data suggested that Nectin-4 expression
might play an important role in pancreatic cancer.
Silencing of Nectin-4 inhibits proliferation of human
pancreatic cancer cell
Furthermore, we directly examined the function of
Nectin-4 in pancreatic cancer cell using siRNA silen-
cing. When transfected with Nectin-4 siRNA in humanpancreatic cancer cell lines, Capan-2 and BxPC-3, for up
to 72 hours, both mRNA and protein expressions of
Nectin-4 were substantially reduced (Figure 4A,B). As a
result, cell proliferation was significantly suppressed by
Nectin-4 gene silencing in these cells (Figure 4C). Data
indicated that Nectin-4 might be critically involved in the
proliferation of Capan-2 and BxPC-3 cells.
Association of Nectin-4 with vascular endothelial growth
factor (VEGF) expression and angiogenesis
We then analyzed the relationship between Nectin-4 and
angiogenesis. There was a significant positive correlation
between Nectin-4 and VEGF expressions determined by
real-time PCR analysis (R = 0.566, P < 0.001; Figure 5A).
We also examined the intratumoral microvessel density
(IMD) by immunohistochemistry (Figure 5B). The micro-
vessel count ranged from 20.7 to 115.0, with the mean
count of 55.9. The percent of Nectin-4 expression level was
significantly correlated with the IMD (R = 0.254, P = 0.005;
Figure 5C). Furthermore, there was also a significant correl-
ation between Nectin-4 status and IMD (P = 0.001; Fig-
ure 5D). These data suggested that Nectin-4 might play
important role in angiogenesis in human pancreatic cancer.
Association between Nectin-4 expression and tumor
infiltrating lymphocytes
Finally, we investigated the immunomodulatory function
of Nectin-4 in human pancreatic cancer. We performed
immunohistochemical analysis of TILs including CD4,
CD8, and CD45RO. The mean numbers of CD4+, CD8+,
and CD45RO+ T cells counts were 165.0, 199.5, and
205.9, respectively. As a result, there were no significant
correlations of tumor Nectin-4 expression with TILs in
any T cell subsets (data not shown).
Discussion
Accumulating evidence indicates that the nectins and
Necls belonging to the nectin family have diverse
physiological and pathological functions in humans
[12-14]. Nectins have been originally investigated in cell
adhesion, and play critical roles in various physiological
conditions including tissue development. Besides physio-
logical roles, nectins and Necls have also been shown to
play important roles in tumor biology [32,33]. In particular,
there are only limited studies on Nectin-4 in tumor biology
and clinical cancers [17-20]. This study focused on the
clinical significance of Nectin-4 expression in pancreatic
cancer. We first examined Nectin-4 expression in actual
pancreatic cancer tissue by immunohistochemistry. As a
result, the intense expression was found in most human
pancreatic cancer tissues, while limited expression was ob-
served in non-cancer tissues of the pancreas. Interestingly,
patients with high Nectin-4 expression had significantly
poor prognosis in comparison with patients with low
Figure 3 Correlation between the Nectin-4 and Ki67 expression in human pancreatic cancer. (A) Representative case of Ki67 expression.
Original magnification, ×200. (B) There was a significant correlation between the percent of positive Nectin-4 and Ki67 expression levels (R = 0.436,
P < 0.001, Spearman’s rank test). (C) The tumors with high Nectin-4 status had a significantly higher percentage of Ki67-positive tumor cells than the
tumors with low Nectin-4 status (*P <0.001, Mann-Whitney U test).
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analysis demonstrated that tumor Nectin-4 status was
defined as a significant independent prognostic factor for
pancreatic cancer patients. A few previous reports have
shown that Nectin-4 expression contributes to the
postoperative prognosis of patients with malignant tumors
including lung adenocarcinoma and breast cancer [17,19].
Our finding was consistent with these previous studies.
On the other hand, Nectin-4 expression was not defined
as a prognostic factor in ovarian cancer [18]. Therefore,
the prognostic value of Nectin-4 may be dependent on the
tumor type. In this study, there were no correlations of
Nectin-4 expression with various clinicopathological
factors in pancreatic cancer. Data suggested that Nectin-4
might play functionally important roles in tumor pro-
gression and metastasis independently of the TNM
classification. However, the underlying mechanism forTable 2 Univariate and multivariate prognostic analysis of 12
Characteristics Univariate analysis
HR 95% Cl
Age (66 vs. <66) 0977 0.672-1422
Gender (Female vs. Male) 1001 0.683-1468
Tumor Status (T3-4vs. T1-2) 1.735 1.106-2.720
Nodal Status (N1 vs. N0) 1.837 1.240-2.720
Metastatic status (M1 vs. M0) 4450 2323-8525
Residual Tumor (R1-2 vs. R0) 2.014 1.372-2958
Histopathological grading (G3-4 vs. G1-2) 1.361 0.810-2 285
Ki67 (High vs. Low) 1462 1.004-2 129
Nectin-4 status (High vs. Low) 1.628 1.105-2.398
aCox regression model.
bSignificant difference.
HR, hazard ratio; CI, confidence interval.the prognostic value of Nectin-4 remains unclear.
Noyce et al. have reported that Nectin-4 is highly
expressed in several tumor cells and plays a key role for
virus entry [34]. Such a unique property of Nectin-4 may
be involved in patient prognosis. Further studies will be
warranted to determine the association between Nectin-4
expression and virus infection in actual pancreatic cancer.
We then investigated the potential roles of Nectin-4 in
pancreatic cancer, and found several important findings.
First, Nectin-4 might be involved in the proliferation of
pancreatic cancer cells. This was demonstrated by the
positive correlation between Nectin-4 and Ki67 expressions.
Furthermore, it was also supported by the data showing
that the siRNA knockdown of Nectin-4 significantly inhibits
the proliferation of human pancreatic cancer cells. In fact,
Takano et al. have reported a similar finding that Nectin-4
inhibition using siRNA significantly suppressed the cell3 patients with pancreatic cancer
Multivariate analysis
P-valuea HR 95% Cl P-valuea
0905 1007 0.681-1,490 0.973
0996 1021 0.691-1508 0.918
0.016b 1.136 0.649-1.990 0.655
0.002b 1.387 0.877-2.193 0.162
<0.001b 2.713 1.352-5.446 0.005b
<0.001b 1.811 1179-2.781 0.007b
0245 1 606 909-2 839 0.103
0.048b 1 096 697-1.721 0.692
0.014b 1.721 1.085-2.730 0.021b
Figure 4 Inhibition of Nectin-4 expression by gene silencing decreases cell proliferation in pancreatic cancer cells. (A,B) Capan-2 and
BxPC-3 cells were transfected with Nectin-4 siRNA or control RNA. The relative expression of Nectin-4 was significantly reduced in both cells when
transfected with Nectin-4 siRNA for up to 72 hours as determined by quantitative real-time PCR and Western blot analysis (n = 4 of each group).
(C) Cell proliferation was significantly inhibited by Nectin-4 gene silencing in both cells after 72 hours incubation as determined by MTS assay (n = 6 of
each group). *P < 0.001 versus control siRNA (Student’s t test).
Figure 5 Relationships between Nectin-4 expression and angiogenesis in human pancreatic cancer. (A) Positive correlation between
Nectin-4 and VEGF expression in human pancreatic cancer by quantitative real-time PCR (n = 38, R = 0.566, P < 0.001, Spearman’s rank test).
(B) Representative immunohistochemical staining of CD31 in human pancreatic cancer tissues. Original magnification × 200. (C) There was a
significant correlation between the percent of positive Nectin-4 and intratumoral microvessel density (R = 0.254, P = 0.005, Spearman’s rank test).
(D) The intratumoral microvessel density in the tumors with high Nectin-4 status was significantly higher than that in the tumors with low
Nectin-4 status (*P =0.001, Mann-Whitney U test).
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together, Nectin-4 may be a critical factor contribut-
ing to the progression in certain human cancers. Further-
more, direct targeting of Nectin-4 may have therapeutic
potential for cancer treatment. Therefore, it may be valu-
able to generate and evaluate either monoclonal antibody
or small molecule compound targeting human Nectin-4.
Second, we found that there was a positive correlation
of tumor Nectin-4 expression with VEGF expression and
IMD in pancreatic cancer. Angiogenesis is widely accepted
to play a key role in tumor growth and metastasis. And
VEGF is the dominant angiogenic factor in the tumor
microenvironment [35,36]. We and others have previously
shown that prognostic importance and significant involve-
ment of angiogenesis in pancreatic cancer [29,30,37]. It
has recently been reported that one of nectin family,
Necl-5/CD155 interacts with VEGF and induces angiogen-
esis in human vascular endothelial cells [22]. The members
of the nectin family are known to exert a similar function
and to act interactively under various conditions [12-14,38].
Therefore, we hypothesized that Nectin-4 might be associ-
ated with angiogenesis in pancreatic cancer. Although the
precise underlying mechanism is still not revealed, our data
suggested that Nectin-4 might be critically involved in
tumor angiogenesis in pancreatic cancer. Targeting VEGF
is currently a standard treatment for some human malig-
nancies including colorectal and lung cancers. Nectin-4
blockade may enhance the effect of the inhibition of VEGF
in cancer treatment. Further fundamental studies are
needed to reveal the molecular mechanisms of Nectin-4
in association with angiogenesis, and to develop new
therapeutic strategy.
Previous studies have demonstrated that some of
the nectin family members specifically interact with
the receptors on several immune cells, including T
cells and NK cells, and exert immunological functions
[23-27]. In addition, it has been also suggested that
some members might play an important role in the
tumor immunosurveillance [32,33]. We and others
have reported that tumor-infiltrating CD4+, CD8+, or
CD45RO+ T cells have a significant prognostic value
in several human cancers, including pancreatic cancer
[39-44]. Therefore, we finally evaluated the role of
Nectin-4 in tumor immunity. As a result, we found no sig-
nificant correlations between Nectin-4 expression and the
several subsets of TILs, suggesting that Nectin-4 may have
little role in modulating immune response in actual
pancreatic cancer. However, careful evaluation in larger
scale studies will be needed to reach a definitive conclusion.
Conclusions
We have shown for the first time that Nectin-4 is overex-
pressed in human pancreatic cancer. Most importantly,
tumor Nectin-4 expression has a significant prognosticvalue in patients with pancreatic cancer. In addition, our
data suggest that Nectin-4 may contribute to tumor
proliferation and angiogenesis. Further studies may be
warranted to develop novel therapies targeting Nectin-4
for human malignant diseases.
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